| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 44 | 2023 | 1063 | 4.170 |
Why?
|
| Carcinoma, Squamous Cell | 26 | 2018 | 1097 | 2.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 29 | 2021 | 2567 | 1.610 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 275 | 1.330 |
Why?
|
| Antineoplastic Agents | 16 | 2019 | 2415 | 1.280 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 187 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 92 | 0.670 |
Why?
|
| Sarcoma | 5 | 2015 | 220 | 0.640 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 1553 | 0.590 |
Why?
|
| ErbB Receptors | 4 | 2016 | 501 | 0.590 |
Why?
|
| Biopsy | 2 | 2019 | 1185 | 0.540 |
Why?
|
| Bone Neoplasms | 3 | 2013 | 329 | 0.440 |
Why?
|
| Taxoids | 5 | 2014 | 130 | 0.430 |
Why?
|
| Combined Modality Therapy | 18 | 2010 | 1720 | 0.410 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 117 | 0.410 |
Why?
|
| Paclitaxel | 11 | 2008 | 479 | 0.400 |
Why?
|
| Fluorouracil | 14 | 2014 | 560 | 0.390 |
Why?
|
| Humans | 73 | 2023 | 89447 | 0.390 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 969 | 0.370 |
Why?
|
| Aged | 40 | 2021 | 19186 | 0.350 |
Why?
|
| Survival Rate | 13 | 2019 | 1903 | 0.340 |
Why?
|
| Neoplasms | 7 | 2023 | 3043 | 0.330 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2003 | 166 | 0.330 |
Why?
|
| Radiotherapy | 1 | 2010 | 334 | 0.310 |
Why?
|
| Middle Aged | 39 | 2021 | 26010 | 0.290 |
Why?
|
| Male | 46 | 2021 | 42461 | 0.280 |
Why?
|
| Osteosarcoma | 2 | 2004 | 161 | 0.280 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2006 | 5 | 0.270 |
Why?
|
| Hydroxyurea | 12 | 2014 | 239 | 0.270 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 6817 | 0.270 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 16 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 5 | 2015 | 1412 | 0.260 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 62 | 0.260 |
Why?
|
| Prognosis | 12 | 2019 | 3789 | 0.260 |
Why?
|
| Adult | 34 | 2021 | 26648 | 0.260 |
Why?
|
| Female | 45 | 2021 | 46267 | 0.250 |
Why?
|
| Advance Care Planning | 2 | 2016 | 45 | 0.240 |
Why?
|
| Deglutition Disorders | 3 | 2018 | 119 | 0.240 |
Why?
|
| Treatment Outcome | 16 | 2018 | 8251 | 0.230 |
Why?
|
| Melanoma | 2 | 2021 | 468 | 0.220 |
Why?
|
| Skin Neoplasms | 2 | 2006 | 581 | 0.220 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2004 | 128 | 0.220 |
Why?
|
| Hemangiosarcoma | 3 | 2012 | 17 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 1365 | 0.210 |
Why?
|
| Quality of Life | 8 | 2018 | 1669 | 0.210 |
Why?
|
| Quinazolines | 3 | 2010 | 221 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 112 | 0.210 |
Why?
|
| Disease-Free Survival | 11 | 2013 | 1214 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 286 | 0.200 |
Why?
|
| Cetuximab | 3 | 2012 | 117 | 0.190 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 502 | 0.190 |
Why?
|
| Lactones | 1 | 2001 | 27 | 0.190 |
Why?
|
| Ipilimumab | 1 | 2021 | 62 | 0.190 |
Why?
|
| Breast Neoplasms | 4 | 2001 | 3013 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 159 | 0.180 |
Why?
|
| Spouses | 1 | 2020 | 32 | 0.180 |
Why?
|
| Trastuzumab | 1 | 2020 | 74 | 0.180 |
Why?
|
| Thrombosis | 1 | 2023 | 302 | 0.180 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2000 | 97 | 0.170 |
Why?
|
| Alanine | 1 | 2019 | 83 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2003 | 277 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1996 | 890 | 0.170 |
Why?
|
| Triazines | 1 | 2019 | 53 | 0.160 |
Why?
|
| Antibodies | 1 | 2020 | 353 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 117 | 0.160 |
Why?
|
| Medical Oncology | 3 | 2016 | 384 | 0.160 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2018 | 15 | 0.160 |
Why?
|
| Lymphoma | 1 | 2000 | 265 | 0.160 |
Why?
|
| Neoplasm Staging | 12 | 2015 | 2017 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 3 | 2013 | 260 | 0.150 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2015 | 45 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 1800 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2000 | 270 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2000 | 298 | 0.150 |
Why?
|
| Communication | 1 | 2020 | 458 | 0.140 |
Why?
|
| Intubation, Intratracheal | 1 | 2018 | 146 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2760 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 1110 | 0.140 |
Why?
|
| Terminal Care | 2 | 2016 | 137 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2016 | 70 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 48 | 0.130 |
Why?
|
| Drug Design | 1 | 2016 | 127 | 0.130 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.130 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 895 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2016 | 113 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 173 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2015 | 83 | 0.120 |
Why?
|
| Bone Marrow | 1 | 1996 | 445 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2004 | 172 | 0.120 |
Why?
|
| Camptothecin | 2 | 2009 | 196 | 0.120 |
Why?
|
| Outpatients | 1 | 2014 | 100 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2016 | 198 | 0.120 |
Why?
|
| Self Care | 1 | 2015 | 165 | 0.120 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 1150 | 0.110 |
Why?
|
| Health Personnel | 1 | 2016 | 215 | 0.110 |
Why?
|
| Health Promotion | 1 | 2015 | 165 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 2364 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 132 | 0.110 |
Why?
|
| Incidence | 5 | 2008 | 1597 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 839 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 209 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3667 | 0.110 |
Why?
|
| Spinal Cord | 1 | 1994 | 255 | 0.110 |
Why?
|
| Carboplatin | 4 | 2008 | 312 | 0.110 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2012 | 9 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 618 | 0.100 |
Why?
|
| Radiotherapy Dosage | 5 | 2006 | 470 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 146 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 364 | 0.100 |
Why?
|
| Sirolimus | 1 | 2013 | 170 | 0.100 |
Why?
|
| Risk Factors | 5 | 2023 | 5500 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 314 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 576 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 318 | 0.090 |
Why?
|
| Salvage Therapy | 4 | 2008 | 236 | 0.090 |
Why?
|
| Methotrexate | 1 | 2011 | 250 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2016 | 687 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 651 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2014 | 455 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 2633 | 0.090 |
Why?
|
| Developing Countries | 1 | 2010 | 77 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 198 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 359 | 0.090 |
Why?
|
| Remission Induction | 4 | 2008 | 740 | 0.090 |
Why?
|
| Leiomyoma | 1 | 2013 | 202 | 0.080 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2008 | 4 | 0.080 |
Why?
|
| United States | 5 | 2010 | 7005 | 0.080 |
Why?
|
| Time Factors | 4 | 2015 | 5341 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 66 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 90 | 0.080 |
Why?
|
| Administration, Oral | 4 | 2012 | 682 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 605 | 0.080 |
Why?
|
| Blood Coagulation Disorders | 1 | 2008 | 66 | 0.070 |
Why?
|
| Interdisciplinary Communication | 2 | 2008 | 131 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2020 | 782 | 0.070 |
Why?
|
| Cisplatin | 3 | 2014 | 618 | 0.070 |
Why?
|
| Transplantation, Autologous | 2 | 2000 | 344 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 315 | 0.070 |
Why?
|
| Doxorubicin | 2 | 2015 | 303 | 0.070 |
Why?
|
| Heart Failure | 1 | 2016 | 1186 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2016 | 3388 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4297 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 871 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2003 | 1012 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2012 | 1534 | 0.060 |
Why?
|
| Young Adult | 5 | 2015 | 6323 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2284 | 0.060 |
Why?
|
| Dermatofibrosarcoma | 1 | 2004 | 13 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2004 | 11 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2004 | 576 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 221 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 42 | 0.060 |
Why?
|
| Chondrosarcoma | 1 | 2004 | 48 | 0.060 |
Why?
|
| Neck Dissection | 1 | 2004 | 67 | 0.060 |
Why?
|
| Adolescent | 6 | 2018 | 9272 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 173 | 0.060 |
Why?
|
| Factor V | 1 | 2023 | 9 | 0.060 |
Why?
|
| Prothrombin | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 29 | 0.060 |
Why?
|
| Travel | 1 | 2003 | 71 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2006 | 900 | 0.050 |
Why?
|
| Uracil | 2 | 1999 | 55 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2006 | 487 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 20 | 0.050 |
Why?
|
| Bryostatins | 1 | 2001 | 15 | 0.050 |
Why?
|
| Macrolides | 1 | 2001 | 31 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2018 | 9068 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2001 | 109 | 0.050 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2000 | 4 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 1999 | 243 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2000 | 50 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 684 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 272 | 0.040 |
Why?
|
| Breast | 1 | 2001 | 292 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 302 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 283 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1725 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 209 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1999 | 112 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 4143 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 861 | 0.040 |
Why?
|
| Disease Progression | 3 | 2012 | 1489 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2000 | 374 | 0.040 |
Why?
|
| Pyrazines | 1 | 1998 | 94 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2000 | 463 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 43 | 0.030 |
Why?
|
| Cell Separation | 1 | 1996 | 199 | 0.030 |
Why?
|
| Logistic Models | 1 | 2000 | 1213 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 622 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 424 | 0.030 |
Why?
|
| Transitional Care | 1 | 2015 | 18 | 0.030 |
Why?
|
| Age Factors | 1 | 2000 | 1872 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 192 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 529 | 0.030 |
Why?
|
| Cardiology | 1 | 2016 | 115 | 0.030 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 105 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2006 | 296 | 0.030 |
Why?
|
| Veins | 1 | 1994 | 95 | 0.030 |
Why?
|
| Documentation | 1 | 2014 | 103 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 462 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 187 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 234 | 0.030 |
Why?
|
| Recurrence | 1 | 1996 | 1144 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 172 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 152 | 0.030 |
Why?
|
| Arteries | 1 | 1994 | 180 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1994 | 221 | 0.030 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2012 | 15 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2012 | 96 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 338 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1998 | 638 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 154 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2012 | 84 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 80 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2012 | 68 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2012 | 92 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 280 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 309 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 188 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 759 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 374 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 856 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 289 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 350 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 203 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 794 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 520 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1715 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 509 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 1998 | 983 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1225 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 447 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2004 | 549 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 99 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2008 | 2875 | 0.020 |
Why?
|
| Niacinamide | 1 | 2009 | 117 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2008 | 35 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 115 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 186 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 188 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 689 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 216 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 27396 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2560 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2664 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1653 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 50 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 4043 | 0.020 |
Why?
|
| Deglutition | 1 | 2006 | 76 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 155 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 233 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 353 | 0.010 |
Why?
|
| Filgrastim | 1 | 2003 | 57 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 196 | 0.010 |
Why?
|
| Bias | 1 | 2003 | 134 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 90 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 270 | 0.010 |
Why?
|
| Neutropenia | 1 | 2003 | 216 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 683 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1862 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 853 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 988 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 342 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2001 | 101 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 435 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 951 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2000 | 43 | 0.010 |
Why?
|
| Lymphedema | 1 | 2001 | 77 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2000 | 123 | 0.010 |
Why?
|
| Illinois | 1 | 2001 | 483 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 1999 | 28 | 0.010 |
Why?
|
| Tegafur | 1 | 1998 | 17 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 1428 | 0.010 |
Why?
|
| Video Recording | 1 | 2000 | 203 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1943 | 0.010 |
Why?
|
| Etoposide | 1 | 1998 | 206 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 200 | 0.010 |
Why?
|
| Skin | 1 | 2001 | 583 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 809 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 645 | 0.010 |
Why?
|
| Contrast Media | 1 | 2000 | 1092 | 0.010 |
Why?
|